UK: M&A In Life Sciences Set For Revival In 2017

Last Updated: 20 March 2017
Article by Matthew Thaxter

Most Read Contributor in UK, August 2017

This week our colleague Sriram Prakash, Deloitte's global lead for mergers and acquisitions (M&A) insight, published the cross industry M&A Index Outlook for 2017.1 This week's blog draws on the report to explore the outlook for, and key drivers of, M&A in the Life Sciences industry in 2017.

The headline figures and trends from the M&A Index 2017 report include a specific reference to the Life Sciences and Healthcare (LSHC) industry. The insights identified include the following:

  • in 2016, the LSHC sector announced around $215 billion worth of deals - about half the level of the previous two years
  • the value of deals in the pharmaceutical industry in 2016 totalled $75 billion - down from $200 billion in 2015
  • while LSHC volumes remained strong, values declined sharply, driven by the fall in mega-deals
  • only three so called 'mega deals' were announced in 2016, compared to eight in 2015
  • $168 billion worth of announced deals were withdrawn in 2016 compared to $97 billion in 2015
  • the average price to earnings multiple on the 2016 deals still remained relatively high, at 32.6 compared to 35.8 in 2015
  • the US was the most active market and contributed to nearly 60 per cent of the announced deals
  • Europe was the only region that saw an uptick in deals, with France being the most active target country
  • cross-border deals in 2016 stood at $60 billion - down from $154 billion in 2015.

While 2016 failed to reach the levels of deal-making we have become accustomed to, a key contributory factor was the heightened political and economic uncertainty experienced throughout the past year. However, as we look ahead to 2017, there are a number of drivers that point to a year of increased M&A activity within the Life Sciences sector which I explore below.

Last year's political uncertainty, particularly surrounding Brexit and the US presidential elections certainly dampened the appetite for deals, with the associated uncertainty from the pricing and tax environments among the primary drivers of stalled activity. However, Deloitte now expects the new environment in the US to be more favourable for M&A than before. The new US administration is expected to relax corporate tax rates and US-based pharmaceutical companies are now likely to see this as an opportunity to replenish their pipelines with acquisitions of promising smaller peers, rather than re-invest in internal R&D.

The Centre's recent report, Measuring the return from pharmaceutical innovation 2016 further supports the notion that pharmaceutical companies are increasingly likely to pursue external innovation, rather than invest in internal asset development.2 Our analysis found that a growing proportion of the 12 original cohort companies' late-stage pipeline value has become internally-generated (57 per cent in 2016 compared to 39 percent in 2013), but that this correlates with a continued decline in forecast late-stage pipeline value ($833 billion in 2016 compared to $913 billion in 2013). Hence, we predicted in our report that an increase in M&A activity is on the horizon as companies attempt to boost the forecast value of their late-stage pipelines through the purchase of externally-innovated assets.

The Centre's research also found that unprecedented pressure from industry payers has increased the importance of value demonstration, and this will spur collaborations, including M&A, as companies look to better protect against the cost of attrition and provide some risk sharing. Consolidation, particularly within specialist areas will be prevalent, where unmet medical needs create the scope to command high margins. Related to this, the theme of de-diversification is emerging as companies are increasingly focussing on priority areas and exiting non-core areas in order to build positions of leadership within one or two key therapeutic areas (TAs). Our analysis for the R&D report found that companies with less volatility in their late-stage pipeline portfolios tend to achieve higher forecast peak sales per asset, implicating TA focus as strategy for maximum value creation.3

In a broader context, life sciences companies are expected to use M&A as a way to gain access to new markets and new technologies in order to expand their pipelines and sales channels. Deals and partnerships with established and upcoming local firms in emerging markets are likely to continue due to the clear advantage offered by having a local presence. Emerging markets can be very political with a high degree of protectionism towards locally produced products, meaning that deal-making with local producers is often necessary to gain a foothold in these growing markets. Furthermore, life sciences companies are anticipated to continue pursing deals of smaller innovative companies that aid larger life sciences companies increase operational efficiencies and reduce costs across their business functions. Additionally, deals at the convergence between the healthcare and technology sectors are also likely to see an uptick as life sciences companies respond to the need to expand their technical capabilities to enable the management and analysis of increasing amounts of data to drive more informed decision making.4

Ultimately, the environment in 2017 is likely to be more favourable for life sciences companies to pursue M&A activities. Increased deal-making will also be necessary for many companies to both adapt to the changing healthcare landscape and to achieve their strategic objectives.

Footnotes

1. Deloitte M&A Index 2017. See also: https://www2.deloitte.com/uk/en/pages/financial-advisory/articles/deloitte-m-and-a-index.html

2. Deloitte (2016). Measuring the return from pharmaceutical innovation 2016. See also: https://www2.deloitte.com/uk/en/pages/life-sciences-and-healthcare/articles/measuring-return-from-pharmaceutical-innovation.html 

3. Ibid

4. Deloitte M&A Index 2017. See also: https://www2.deloitte.com/uk/en/pages/financial-advisory/articles/deloitte-m-and-a-index.html

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.